©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Cardiovascular drugs in the treatment of infantile hemangioma
Israel Fernandez-Pineda, Lucia Ortega-Laureano, Department of Surgery, St. Jude Children’s Research Hospital, Memphis, TN 38105, United States
Regan Williams, Department of Pediatric Surgery, Le Bonheur Children’s Hospital, Memphis, TN 38105, United States
Ryan Jones, Department of Pediatric Cardiology, Le Bonheur Children’s Hospital, Memphis, TN 38105, United States
Author contributions: Fernandez-Pineda I, Williams R, Ortega-Laureano L and Jones R designed the review article and wrote the manuscript.
Conflict-of-interest statement: The authors declare that there is no conflict of interests.
Correspondence to: Israel Fernandez-Pineda, MD, Department of Surgery, St. Jude Children’s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, United States. israel.fernandez-pineda@stjude.org
Telephone: +1-901-5952315
Received: May 28, 2015
Peer-review started: June 1, 2015
First decision: August 16, 2015
Revised: September 4, 2015
Accepted: October 23, 2015
Article in press: October 28, 2015
Published online: January 26, 2016
Processing time: 238 Days and 5.9 Hours
Peer-review started: June 1, 2015
First decision: August 16, 2015
Revised: September 4, 2015
Accepted: October 23, 2015
Article in press: October 28, 2015
Published online: January 26, 2016
Processing time: 238 Days and 5.9 Hours
Core Tip
Core tip: This article aimed to review the different beta-blockers used in the treatment of children with infantile hemangioma, the pre-treatment cardiologic work-up required and the potential side-effects associated with beta-blockers therapy in such a young population. Other cardiovascular drugs with potential effects on infantile hemangioma including angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are also reviewed.